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Abstract: The etiology of scleroderma (SSc) is unknown; immunogenic stimuli such as infections and vaccinations could 
theoretically be risk factors for scleroderma. Our objective was to assess the relationship between viral and bacterial infec-
tions, and vaccinations, prior to diagnosis of SSc compared to non-inflammatory controls. Methods: A questionnaire was 
sent to individuals with SSc (n =83) and controls (n=351) with non-inflammatory musculoskeletal (MSK) disorders (os-
teoarthritis, n = 204; tendonitis, n = 58; fibromyalgia, n= 89) from a rheumatology practice. Questions ascertained past in-
fections, exposure to infectious agents and vaccination history. Results: The response rate was 78% (SSc) and 56% (MSK 
controls). The mean age was 56 ± 1.6 (SSc) and 58 ± 0.9 (MSK); 88% (SSc) and 82% (MSK) were female. No association 
between prior infections and SSc was observed. In fact, controls were more likely than SSc subjects to report any infec-
tion within 1-year prior to disease diagnosis (35% vs. 16%, p<0.006), or to have suffered a trauma to affected joints prior 
to diagnosis (44% vs. 19%, p<0.0002). Within the 1-year prior to disease diagnosis, controls reported slightly more strep-
tococcal infections (p<0.2), infections with diarrhea and vomiting (p<0.3), and antibiotic use (p<0.09), although none of 
these results were statistically significant. Histories of any hepatitis, rubella, any bacterial infection, and having had a pre-
vious positive tuberculosis skin test were not significantly different between groups and were actually more often reported 
by the control subjects. SSc reported slightly more hepatitis B (p<0.08), more rheumatic fever (p<0.8) in past, and herpes 
zoster (p<0.4), although no differences reached significance. Conclusion: This study does not support that self-report of 
symptomatic infections are more likely to occur ever (prior to diagnosis) or within 1-year prior to symptom onset of SSc, 
or that vaccinations in adulthood trigger SSc.  
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INTRODUCTION 
  Systemic sclerosis (SSc) is a connective tissue disorder 
characterized by excessive deposition of collagen in the skin 
and multiple internal organs [1]. There is some debate as to 
whether SSc is primarily an autoimmune disease or whether 
a positive ANA test is an epiphenomenon of the condition. 
Thus far, immunosuppressive agents have not been very suc-
cessful in treating SSc [2]. The etiology of scleroderma re-
mains unknown, though both genetic and environmental fac-
tors have been implicated [3]. Reports of familial occur-
rences of SSc are infrequent, but can occur, and studies in-
vestigating an underlying genetic predisposition have used 
serological techniques to suggest linkages between SSc and 
HLA-A1;B8;DR3;DR52 haplotypes in certain ethnic popula-
tions such as the Choctaw Indians in Oklahoma and Japanese 
subjects [4]. Furthermore, major histocompatibility complex 
(MHC) analyses have revealed strong associations of HLA 
class II alleles with serologically and clinically defined sub-
sets of SSc [1,5].  
  Early case studies described SSc and acid-fast bacterial 
infections [6-8]. We could also postulate an altered immune 
system or unknown co-factor increasing the risk of both tu-
berculosis (TB) and SSc. Circumstantial evidence for a 
probable infectious cause (via an immune cross-reactivity 
mechanism where increased activation of a gene regulating 
the synthesis of a heat shock protein (HSP) in SSc fibro- 
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blasts) has been described [9]. Others reported that bacterial 
HSPs and serum antibodies to Mycobacterium tuberculosis 
(MTB) HSP65 were present in 47% of SSc patients exam-
ined [10]. A SSc-RA overlap syndrome patient with Myco-
bacterium kansassi pulmonary infection showed improve-
ment in both clinical symptoms and serum levels of IgM-RF 
and anti-mycobacterial HSP65 with anti-tuberculosis treat-
ment [11]. Similarly, regression of skin changes in a patient 
with SSc following treatment for bacterial overgrowth with 
chronic ciprofloxacin has been reported [12]. The high ho-
mology between the microbial and human HSP65 proteins 
support a connection exists between tuberculosis and the 
development of SSc [10, 13]. There are Canadian, Russian 
and Norwegian cases describing temporal presentations of 
TB and SSc [13-15]. However, the majority of SSc patients 
do not have TB. 
  Various viruses, most prominently herpes and retrovi-
ruses, have been described with SSc [16-21]. One study 
found amino acid sequence homologies between both HIV-1 
and HSV-1 proteins and autoimmune nuclear antigens, sug-
gesting that co-expression of heterologous viruses having 
common immunosuppressive functions may generate auto-
antibodies cross-reacting with certain nuclear proteins [16]. 
In 1979, there was a report of varicella occurring prior to 
diagnosis in a patient with SSc [18], although a later study 
found the frequency of varicella in SSc patients to be lower 
than that found in SLE patients (9.5% vs. 46.6%) [22]. Evi-
dence of previous mononucleosis infection over a period of 
three years in 4 of 5 children suffering from localized SSc 
has been reported [17], and another study reported anti-
fibrillarin antibodies in 58% of SSc patients and found that SSc Infectious Triggers  The Open Rheumatology Journal, 2007, Volume 1    13 
sequence homologies between fibrillarin, herpes virus type 1 
and EBV proteins were suggestive of the notion that molecu-
lar mimicry may have played an important role in the induc-
tion of the antibodies [23]. Elevated levels of IgG antibodies 
to CMV and EBV titers have been found in patients with 
SSc [21]. Vaughan et al assayed SSc EBV and CMV in sub-
jects with limited and diffuse SSc after observing that 
autoantibodies to the autoantigen p542 (presumed to be de-
rived from the EBV antigen) occur in both mononucleosis 
and in SSc. Anti-CMV titers were significantly higher in the 
anti-p542 positive SSc patients than they were in anti-p542 
negative patients. Anti-EBV titers were not different be-
tween those positive vs. negative for anti-p542, but were 
higher in all SSc groups than in a healthy control group, 
p<0.02. However, although CMV and EBV findings were 
not significantly different in skin biopsies from 13 SSc and 
17 controls, investigators concluded that the incidence of the 
viruses was high, and they may be related to the process in-
volved in the initiation of autoimmunity in SSc [24].  
  Borrelia burgdorferi (Bb) has been implicated in general-
ized morphea [25]. Additionally, an earlier study found 38% 
of seropositive (n=5) and 23% of seronegative (n=26) pa-
tients with morphea exhibited elevated B.burgdorferi in-
duced lymphocyte proliferation, supporting a causal role, at 
least for some patients with morphea [26]. One study in 
Western Turkey (n=10 subjects with morphea and n=12 sub-
jects with lichen sclerosus) found the presence of Bb DNA in 
30% of morphea and 50% of lichen sclerosus patients sug-
gesting a potential role in both conditions [27]; whereas, 
another study conducted in the U.S.A. (n = 35) did not find 
Bb spirochete in the pathogenesis of morphea and lichen 
sclerosus [28]. A more recent study reviewing the causal role 
of Bb in morphea concluded that previous conflicting results 
of European and American scientists could either be due to 
the fact that Bb is not a causative agent for morphea or that a 
subset of morphea is caused by a special subspecies of Bb 
present in Europe and Asia but not the U.S.A [29]. 
  The evidence surrounding the potential importance of 
retroviruses in SSc is contradictory. One study of antibodies 
to retroviral proteins in SSc found that 8 of 29 SSc patients 
had antibodies to HIV proteins [20]. It was unclear whether a 
retrovirus was involved in the pathogenesis of SSc or 
whether the antibodies cross-reacted (molecular mimicry). 
Studies by Jimenez et al have demonstrated the ability of 
endogenous retroviruses to be expressed into proteins which 
can regulate cellular functions and lead to the occurrence of 
pathological conditions, but no conclusive evidence support-
ing pathogenesis for retroviruses in SSc was found [30, 31]. 
Other studies have found links with paramyxoviruses [32], 
congenital rubella [33], and parvovirus B19 [34]. 
  In light of the existing body of research, it was expected 
that SSc patients would report more infections than a com-
parison group with non-inflammatory musculoskeletal 
(MSK) complaints prior to diagnosis, particularly in the 12 
months prior to symptom onset. This study was designed to 
test if the self-reported frequency of certain infections and 
vaccinations was different between SSc and control groups, 
but also as an exploratory study to determine any potential 
infectious triggers (such as viruses or bacteria) that could be 
studied in greater depth in future research.  
MATERIALS AND METHODOLOGY 
  A five-page questionnaire consisting of 23 questions was 
developed to assess: whether subjects had ever had specific 
infections; whether they had had any infection or antibiotic 
exposure 12 months prior to their SSc diagnosis; travel his-
tory (and any associated illnesses) outside of North America 
in the 12 months preceding; vaccine history since 18 years of 
age; and whether or not they had ever been positive for a TB 
skin test. Specific questions addressed rubella, parvovirus, 
and herpes infections as well as rheumatic fever, illnesses 
that induced rash or fever, and previous hepatitis A, B and C 
exposure. The questionnaire was approved by the University 
of Western Ontario Health Sciences Research Ethics Board 
and it was pre-tested on clinic patients (controls) to ensure 
that it was understandable and that no consistent misinterpre-
tations were being made. The questionnaire had been vali-
dated previously in a study of systemic lupus erythematosus 
(SLE) patients in the same rheumatology practice, which 
reported an increased frequency of herpes zoster clustered 
around the time of diagnosis with SLE [35].  
  The rheumatologist who conducted this research, based 
in London, Ontario, is a clinical expert in scleroderma serv-
icing Southwestern Ontario. Referrals are from a large popu-
lation base of approximately one million, but also from more 
geographically remote northern areas. Although many of the 
SSc cases from the referral catchment area are seen in the 
London clinic, not all cases will be recognized and referred 
to tertiary care, and other cases may be followed elsewhere. 
The challenge of obtaining a representative study sample of 
SSc from clinical cohorts has been described in the literature 
and although estimates vary, it is generally accepted that less 
severe cases will generally be under-represented [36-38].  
  Patient selection was completed using the computerized 
billing system to identify all patients who had been seen in 
the clinic for SSc over the past 2 years and who were current 
patients with accurate addresses. Controls with non-
inflammatory musculoskeletal disorders were subsequently 
chosen at a ratio of 4 controls:1 SSc patient using the same 
method (a billing list based on date of last clinic visit who 
had been seen for non-inflammatory MSK conditions). Con-
trols were over-sampled as it was expected that the response 
rate would be less. The questionnaire was sent to 
scleroderma subjects (n=83, cases) and control subjects 
(n=351), who had non-inflammatory MSK disorders such as 
osteoarthritis (n=204), tendonitis (n=58) and fibromyalgia 
(n=89), from the same practice.  
  All subjects were blinded as to the hypothesis and were 
sent questionnaire packages that included a stamped return 
addressed envelope, a letter of information and the question-
naire. Written informed consent was obtained from the study 
participants. Data were entered and statistical analyses were 
performed using SAS-based JMP statistical software (Ver-
sion 4.0) [39]. Trends in survey responses were studied. For 
each survey question, responses of uncertainty were ex-
cluded from the analyses. Group means, odds ratios and 95% 
confidence intervals were calculated for exposures of inter-
est. 
  In order to further characterize the SSc cohort of subjects 
a post hoc chart review was conducted to obtain information 
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diagnosis with SSc, and the Modified Rodnan skin score 
(MRSS) (MRSS ranges from 0 to 78 with lower scores rep-
resenting less skin involvement) [40] and Health Assessment 
Questionnaire Disability Index (HAQ-DI) (HAQ-DI ranges 
from 0-3 with higher scores indicating more functional dis-
ability) [41].  
RESULTS 
  The response rate in the SSc group was 78% (n=65) and 
in the controls it was 56% (n=196). As can be seen in Table 
1, the mean age was 56 ± 1.6 in the SSc group and 58 ± 0.9 
in the controls (MSK); 88% and 82% were female in the SSc 
and MSK groups. The SSc group was comprised of 37% 
diffuse SSc, had a mean overall MRSS score of 9.5 ± 1.63, 
and a mean HAQ-DI score of 1.12 ±0.106 (Table 2). The 
mean disease duration for the SSc group was 9.75 ± 0.53 
years, and the mean age of diagnosis was 50.05 ± 1.64 years 
old (Table 2). Patients were primarily Caucasian; a very few 
were Native Canadian, Asian or African Canadians.  
  MRSS and HAQ-DI values were determined by subse-
quent chart review to further characterize the cohort of SSc 
subjects who responded to this research questionnaire. 
Scores were available for only 28 and 45, respectively, of the 
65 subjects who participated in the research study.  
  The data in Table 3 show that no association between 
recalled symptomatic prior infections and scleroderma was 
observed. For several types of infections numbers were small 
and results were not statistically significant, and thus, there 
were no meaningful differences in reported infections be-
tween the cases and controls. Frequencies in controls com-
pared to SSc cases included: hepatitis A (3% vs. 1.6%, 
p=0.6), hepatitis B (0% vs. 1.6%, p=0.08), hepatitis C (2% 
vs. 1.6%, p=0.8), hepatitis of any kind (including any of A, 
B, C or if unable to recall which type; 7% vs. 5%, p=0.4), 
rubella (58% vs. 51%, p=0.4), any bacterial infection (78% 
vs. 68%, p=0.1), positive tuberculosis skin test (13% vs. 8%, 
p=0.2), past rheumatic fever (7% vs. 8%, p=0.8), and herpes 
zoster prior to disease diagnosis (8% vs. 12%, p=0.4). Sub-
jects with non-inflammatory MSK disorders were signifi-
cantly more likely to report a previous joint trauma (44% vs. 
19%, p=0.0002), and this finding was used as internal valida-
tion where those with non-inflammatory MSK conditions 
should have more preceding trauma. 
  Data focusing on the 12-month period prior to diagnosis 
of SSc or non-inflammatory MSK disorders demonstrated 
that controls were significantly more likely than SSc subjects 
to report having experienced any infection within the 12 
months prior to disease diagnosis (35% vs. 16%, p<0.006). 
Controls reported that within the year prior to disease diag-
nosis, they had an increased occurrence of: streptococcal 
infections (13% vs. 8%, p<0.3), infections with diarrhea and 
vomiting (15% vs. 10%, p<0.3), and antibiotic use (50% vs. 
34%, p<0.09), although none of these questions were statis-
tically significant (Table 3).  
DISCUSSION 
  We found no trends of increased self-reported infection 
in SSc prior to symptom onset compared to controls. In con-
trast to the literature, our findings did not support that more 
subjects with SSc had been exposed to TB, but the preva-
lence of TB exposure was very low in our series. We did not 
have Lyme disease in either the cases or the controls, as it is 
rare in Southwestern Ontario. Since there were no signals of 
increased infections we did not subset our patients into dif-
fuse and limited, as exploratory analyses were not warranted. 
However, patients with limited SSc may have a long time 
between first symptoms and diagnosis.  
  Consistent with the concept that herpes family viruses 
may be involved in the development of autoimmunity with-
out being the specific triggering event, we have also reported 
Table 1.  Demographic Factors for Subjects with SSc or Non-Inflammatory MSK Disorders. Given as Percentage (N = Total Num-
ber of Subjects who Responded, with Missing Data Excluded) 
  Scleroderma % (N)  Controls % (N)  p-value 
Respondents  78 (65)  56 (196)  0.0002 
Age (mean ±SEM)  56 ± 1.6  58 ± 0.9  0.2 
Female gender  88 (57)  82 (160)  0.2 
 
Table 2.  Characteristics of the Subjects in the London, Ontario SSc Cohort who Responded to the Study Questionnaire. Given as 
Mean ± SEM or as Percentage (Where Applicable). The Total Number of Subjects for whom a Measurement of the 
Characteristic was Available has been Indicated in Parentheses 
Characteristics of the SSc Study Sample (N=65)  N  Proportion/Mean  Min, Max 
Diffuse disease   65 37%  (65)  - 
Disease duration   64  9.75 ± 0.53   2, 26 
Age at diagnosis   64  50.05 ± 1.64  21, 80 
Modified Rodnan Skin Score (MRSS)    28  9.5 ± 1.63  2, 41 
Health Assessment Questionnaire Disability Score (HAQ-DI)  45  1.12 ±0.106  0, 2.625 SSc Infectious Triggers  The Open Rheumatology Journal, 2007, Volume 1    15 
a temporal clustering of varicella zoster virus (VZV) 
reactivation around the time of disease diagnosis in patients 
with systemic lupus erythematosus, whereby VZV infections 
were clustered just prior to or after diagnosis in SLE but 
were more widely temporally spaced in the controls (the 
mean time until VZV reactivation in SLE subjects was 1 ± 
4.5 years after the diagnosis of SLE, compared to controls 
which was 14.7 ± 4 years before the diagnosis of non-
inflammatory MSK disorder; p<0.003) [35]. However, no 
longitudinal study has demonstrated that a viral illness can 
increase the risk of scleroderma (2). Fifty SSc patients were 
negative for anti-HEV antibodies (all patients tested), sug-
gesting that hepatitis E is not involved in the pathogenesis of 
SSc [42]. 
  This case control survey study provided no evidence that 
the occurrence of infectious events (either bacterial or viral) 
was more common in the one-year period prior to the devel-
opment of SSc compared to controls with non-inflammatory 
MSK conditions. In fact, the study controls were more likely 
to report having had a bacterial infection ever prior to diag-
nosis, or any infection in the one-year prior to disease diag-
nosis. Although it appears that there is no relationship be-
tween self-reported infectious exposures and the subsequent 
development of SSc, this relationship may be modified by 
genetics or other unknown factors. If this paradigm holds, 
then only certain susceptible people would develop SSc fol-
lowing exposure to an infectious agent. Thus, the rates of 
infections could be similar between the cases and controls, 
but the underlying genetics (or other unknown modifying 
factors) could alter the response to the infectious agent in a 
way that would result in the development of SSc only in 
those with a certain genetic complement. It is also possible 
that genetic factors, as well as several types of exogenous 
factors, could be required for scleroderma to develop, and 
hence infectious triggers may be involved in the etiology of 
SSc but exert an effect as part of a complicated process of 
disease development.  
  Our data do not support previous studies that found a 
causal link between infectious triggers and the subsequent 
development of SSc; but SSc patients were slightly (but not 
significantly) more likely than controls to report previous 
herpes zoster infections, and others have also observed this 
[2]. A case control study using objective evidence of past 
infection with herpes zoster will be needed to clarify the link 
between the two. Given that IgG antibodies have been found 
at increased levels in certain herpes viruses in scleroderma 
[2], and herpes viruses have been detected in SSc patients in 
several case studies [18, 22], and that studies have found 
sequence homologies between herpes virus and endogenous 
proteins [21], the possible association between herpes vi-
ruses and SSc merits further research.  
  This study has limitations. These include the lower re-
sponse rate in the control group, and that recall bias may 
have occurred. The differential response rate in the controls 
is likely due to the fact that the SSc patients in this cohort 
Table  3.  Infections, Vaccinations and/or Trauma Experienced (Ever) Prior to Diagnosis, or One-Year Prior to Diagnosis of 
SSc/Non-Inflammatory MSK Disorder. Given as Percentage (N) 
Infection(s) Ever 
Prior to Diagnosis 
Scleroderma % (N)  Controls % (N)  p-value  OR Scl vs. controls  95 % CI 
Bacterial infections  68 (59)  78 (177)  0.1  0.59  (0.31,1.14) 
Hepatitis A  1.6 (62)  3 (186)  0.6  0.59  (0.07,5.18) 
Hepatitis B  1.6 (62)  0 (186)  0.08  -  - 
Hepatitis C  1.6 (62)  2 (186)  0.8  0.74  (0.08,6.80) 
Herpes zoster   12 (60)  8 (192)  0.4  1.45  (0.57,3.72) 
Parvovirus  1.6 (62)  0 (186)  0.2  -  - 
Rheumatic fever  8 (62)  7 (186)  0.8  1.17  (0.40,3.40) 
Rubella  51 (49)  58 (144)  0.5  0.76  (0.40,1.47) 
Tuberculosis skin test  8 (64)  13 (188)  0.2  0.55  (0.20,1.51) 
Vaccinations  49 (59)  50 (189)  0.9  0.95  (0.53,1.72) 
Trauma prior  19 (64)  44 (195)  0.0003  0.30  (0.15,1.59) 
Infections 1-Year 
Prior to Diagnosis 
Scleroderma % (N)  Controls % (N)  p-value   OR Scl vs. controls  95% CI 
Any infection  16 (51)  35 (163)  0.006  0.34  (0.15,0.78) 
Streptococcal throat 
infection 
8 (53)  13 (157)  0.3  0.53  (0.17,1.62) 
Antibiotic use  34 (35)  50 (111)  0.09  0.51  (0.23,1.13) 
Please note: the total number of subjects (N) who responded to each question was variable, as subjects may have skipped questions for which they were uncertain, and if they indi-
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were followed regularly (usually twice a year), whereas 
many OA or other non-inflammatory patients are seen less 
often (if followed at all) and may be less apt to complete a 
questionnaire. Additionally, those with SSc (especially dif-
fuse SSc) may attach more importance to research to identify 
the etiology of their potentially life-threatening disease com-
pared to patients with OA or other MSK conditions who may 
have been told that their disease has at least partially been 
caused by trauma or “wear and tear” of joints. 
  Further limitations included that this retrospective study 
had patients remember infections 1-year prior to diagnosis, 
which may have occurred (on average) more than nine years 
ago. However, patients often search for answers and may 
over interpret events that occurred prior to disease onset, so 
the bias should have been that more infections were found in 
the SSc group due to a diagnosis of a serious disease. Pa-
tients may have misinterpreted survey questions, but this 
should not have been different between the two groups. If 
there was recall bias, we would have expected it to occur in 
favour of our hypothesis of increased infection in SSc; how-
ever, this was not the case. Additionally, asymptomatic in-
fections would not be reported in either group. Diagnostic 
and viral serologic tests were not done. However, past re-
search has been conducted for which self-report of medical 
conditions by subjects with SSc has been validated [43].  
CONCLUSION 
  Self-report of infections prior to diagnosis in SSc is not 
increased compared to non-inflammatory controls. This 
study does not support that self-report of symptomatic infec-
tions are more likely to occur prior to diagnosis ever or 
within 1-year prior to symptom onset of SSc, or that vaccina-
tions in adulthood trigger SSc.  
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